ORKAOruka Therapeutics, Inc.

HealthcareUSD
$99.48

The financials

Oruka Therapeutics, Inc. by the numbers

Oruka Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$50M−$28Mn/a
Net income−$41M−$25Mn/a
Diluted EPSn/a−$0.46n/a

Biotechnology

Ranks #10 of 145 by Smart Score

Compare peers
CAI+3.0%
Caris Life Sciences, Inc.
CRSP+0.80%
CRISPR Therapeutics AG
DNTH+0.85%
Dianthus Therapeutics, Inc.
MANE+1.8%
Veradermics, Incorporated
XENE+2.2%
Xenon Pharmaceuticals Inc.
TVTX+2.3%
Travere Therapeutics, Inc.